This story is Part II of a series on respiratory syncytial virus vaccines. Here we describe the groundbreaking research that is both answering questions about the past vaccine failure and mapping a ...

A recent review published in Cytokine & Growth Factor Reviews discussed the structure and life cycle of respiratory syncytial virus (RSV), the current research on the treatment and prevention of RSV ...

An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that could ...

Structure of RSV, showing its RNA and protein components that enable cell attachment and invasion. The virus impacts multiple body systems, including the respiratory, cardiovascular, and digestive ...

An experimental vaccine against respiratory syncytial virus (RSV), one of the leading causes of infectious disease deaths in infants, has shown early promise in a Phase 1 human clinical trial. A team ...

ATLANTA—An oral antiviral drug that targets a key part of the respiratory syncytial virus (RSV) polymerase and inhibits the synthesis of viral genetic material has been identified, a finding that ...

Jane Tuckerman is an investigator on a project grant sponsored by Industry. Her institution has received funding from Industry (GSK) for investigator led research. She does not receive any personal ...

July 10 (Reuters) - Britain's health regulator approved GSK's GSK.L vaccine for the respiratory syncytial virus (RSV), which causes thousands of hospitalisations and deaths annually, the drugmaker ...

When most people think of respiratory syncytial virus (RSV), they usually think of babies. But you can get it at any age. And if you’re older than 60, you’re at even greater risk for RSV. “The virus ...

Respiratory syncytial virus is one of the leading causes of death for infants globally, and a safe vaccine has yet to be approved for use. In Parts I and II of this series we discussed the magnitude ...